Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 8/20 | 0.50 |
| ▸ | AXL | P30530 | 4/20 | 0.50 |
| ▸ | MERTK | Q12866 | 3/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.38 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.38 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377685 | 0.85 | TYRO3 (0.49) | TYRO3AXLMERTKACVRL1 | |
| SCHEMBL19377710 | 0.83 | ACVRL1 (0.44) | TYRO3AXLMERTKACVRL1MTOR | |
| SCHEMBL31391141 | 0.80 | ACVRL1 (0.49) | TYRO3AXLACVRL1MTORRICTOR | |
| SCHEMBL19377750 | 0.78 | MERTK (0.52) | TYRO3AXLMERTKACVRL1MTOR | |
| SCHEMBL16011302 | 0.77 | ACVRL1 (0.58) | TYRO3AXLACVRL1MTORRICTOR | |
| SCHEMBL19429526 | 0.77 | ACVRL1 (0.45) | ACVRL1MTORRICTORRPTORMAPKAP1 | |
| SCHEMBL16011301 | 0.77 | ACVRL1 (0.58) | TYRO3AXLACVRL1MTORRICTOR | |
| SCHEMBL19377678 | 0.76 | AXL (0.48) | TYRO3AXLMERTKACVRL1MTOR | |
| SCHEMBL23834517 | 0.75 | INSR (0.41) | TYRO3AXLMERTKACVRL1MAP4K4 | |
| SCHEMBL23834512 | 0.75 | INSR (0.41) | TYRO3AXLMERTKACVRL1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3436461-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-11-15 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | TYRO3 96/4885AXL 107/4885MERTK 16/4885 |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | TYRO3 106/4885AXL 49/4885MERTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.